<DOC>
	<DOCNO>NCT00306098</DOCNO>
	<brief_summary>SPECIFIC AIMS : 1 . To reverse hyperglycemia insulin dependency patient Type 1 Diabetes Mellitus islet cell transplantation ; 2 . To eliminate incidence hypoglycemia coma unawareness patient Type 1 Diabetes Mellitus islet cell transplantation ; 3 . To assess long-term safety function successful islet cell transplant patient Type 1 Diabetes Mellitus ; 4 . To determine whether natural history microvascular , macrovascular neuropathic complication Diabetes Mellitus alter follow successful transplantation islet cell ; 5 . To assess effect infliximab prevent early islet destruction , thereby eliminate need second donor 's islet cell . 6 . To assess effect etanercept prevent early islet destruction . 7 . To assess effect exenatide improve islet graft function survival subject return use exogenous insulin . 8 . To assess ability exenatide improve islet survival time transplantation .</brief_summary>
	<brief_title>Islet Cell Transplantation Alone Patients With Type 1 Diabetes Mellitus : Steroid-Free Immunosuppression</brief_title>
	<detailed_description>This Phase II trial 3 group : Group A receive islet 2 donor receive infliximab . Group B receive , addition Daclizumab , Sirolimus , Tacrolimus , dose infliximab islet single donor , per Edmonton protocol . Everything else clinical trial group . The first 4 patient assign Group A , next 4 patient Group B , next 4 patient Group A , next 4 patient Group B ( total =16 ) . Patients Group A receive 1-2 transplant cell 2 donor . If second donor pancreas receive satisfactory time first pancreas , one islet infusion use infuse cell donor . If second pancreas receive first transplantation , second islet infusion do . A second course five dos Daclizumab start day second islet infusion ) . In order determine prolong administration etanercept , combination transplantation culture islet , prevent TNF-α production enhance engraftment , add Group C current protocol . Group C , addition Daclizumab , Sirolimus , Tacrolimus , receive Etanercept peri-transplant period islet one donor . The last 24 patient include Protocol Group C new , Group A B Supplemental Infusion previous transplant . Any Group A B participant eligible supplemental infusion receive etanercept infliximab .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>1 . Patients 18 65 year age 2 . Patients type 1 diabetes mellitus 5 year duration 3 . One following : Hypoglycemia unawareness judge history blood sugar &lt; 54 glucometer without symptom and/or hypoglycemic episode require assistance either family , glucagon administration emergency service Poor diabetes control ( HbA1c &gt; 8 % &gt; 2 visits/yr hospital treatment ketoacidosis ) despite intensive insulin therapy Progressive complication type 1 diabetes mellitus 4 . Body Mass Index ( BMI ) ≤26 1. cpeptide &gt; 0.3ng/ml basal stimulate ; 2. untreated proliferative diabetic retinopathy ; 3 . HbA1C &gt; 12 % ; 4. creatinine clearance &lt; 60 ; 5. serum creatinine consistently &gt; 1.6 mg/dl ; 6. macroalbuminuria &gt; 300mg albumin 24 hour ; 7. presence panel reactive antibody ( PRA ) &gt; 20 % ; 8. previous/concurrent organ transplantation ( except previous unsuccessful islet cell transplant ; 9. malignancy previous malignancy ( except nonmelanomatous skin cancer ) ; 10. xray evidence pulmonary infection ; 11. active infection ; 12. active peptic ulcer disease , gall stone , hemangioma , portal hypertension 13. serological evidence HIV , HbsAg HCV ; serological evidence active EBV ( IgM &gt; IgG ) EBV negative serology ; 14 . PPD conversion positive PPD without historic completion appropriate prophylactic treatment ; 15. abnormal liver function test ; 16. anemia ( hemoglobin &lt; 12.0 ) ; 17. hyperlipidemia ( fast serum triglyceride &gt; 200mg/dl and/or fast serum cholesterol &gt; 240 mg/dl and/or fast LDL cholesterol &gt; 140 mg/dl ) ; 18 . BMI 26 ; 19. unstable cardiovascular status ; prostate specific antigen ( PSA ) &gt; 4 ; 20. pregnancy breastfeeding ; 21. sexuallyactive female : ) postmenopausal , b ) surgically sterile , c ) use acceptable method contraception ( oral contraceptive , Norplant , DepoProvera , barrier device acceptable ; condom use alone acceptable ) ; 22. alcohol abuse , substance abuse smoking within previous 6 month ; insulin requirement &gt; 1u/kg/day condition circumstance make unsafe undergo islet cell transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Transplantation , Islets Langerhans</keyword>
</DOC>